NASDAQ:INTI - Inhibitor Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Inhibitor Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.04 -0.03 (-41.10 %) (As of 03/27/2020 04:00 PM ET) Add Compare Today's Range$0.04Now: $0.04▼$0.0450-Day Range$0.04MA: $0.07▼$0.0852-Week Range$0.01Now: $0.04▼$0.14Volume685 shsAverage Volume51,870 shsMarket Capitalization$15.93 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAdvanced ChartEarningsInsider TradesHeadlinesSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Inhibitor Therapeutics Inc. operates as a pharmaceutical development company that discovers, develops, and plans to commercialize therapeutics to inhibit the progression of cancerous and non-cancerous proliferation disorders in the United States. The company's Hedgehog signaling pathway is a primary regulator of cellular processes in vertebrates, including cell differentiation, tissue polarity, and cell proliferation. It focuses on developing its lead product, SUBA-Itraconazole, a patented oral formulation for prostate and lung cancer. The company was formerly known as HedgePath Pharmaceuticals, Inc. and changed its name to Inhibitor Therapeutics Inc. in August 2019. Inhibitor Therapeutics Inc. was founded in 1992 and is based in Tampa, Florida.Read More Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biotechnology Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:INTI Previous Symbol CUSIPN/A CIKN/A Webhttp://www.inhibitortx.com/ Phone813-864-2559Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/APrice-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AProfitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees2 Outstanding Shares370,446,000Market Cap$15.93 million Next Earnings Date4/2/2020 (Estimated) OptionableNot Optionable Receive INTI News and Ratings via Email Sign-up to receive the latest news and ratings for INTI and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:INTI Rates by TradingView Inhibitor Therapeutics (NASDAQ:INTI) Frequently Asked Questions How has Inhibitor Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Inhibitor Therapeutics' stock was trading at $0.0756 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, INTI shares have decreased by 43.1% and is now trading at $0.0430. View which stocks have been mosted impacted by Coronavirus. When is Inhibitor Therapeutics' next earnings date? Inhibitor Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, April 2nd 2020. View our earnings forecast for Inhibitor Therapeutics. Has Inhibitor Therapeutics been receiving favorable news coverage? News stories about INTI stock have been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Inhibitor Therapeutics earned a media sentiment score of 0.8 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the immediate future. View the latest news aboutInhibitor Therapeutics. Who are some of Inhibitor Therapeutics' key competitors? Some companies that are related to Inhibitor Therapeutics include Neuren Pharmaceuticals (NEU), OncoCyte (OCX), Monash IVF Group (MVF), CorMedix (CRMD), Ampio Pharmaceuticals (AMPE), Exicure (XCUR), Ibio (IBIO), Arix Bioscience (ARIX), Senesco Technologies (ELOX), Kainos Group (DXRX), IMV (IMV), Imugene (IMU), Burcon NutraScience (BU), Novoheart (NVH) and Cynata Therapeutics (CYP). Who are Inhibitor Therapeutics' key executives? Inhibitor Therapeutics' management team includes the following people: Mr. Nicholas Jon Virca, Pres & CEO (Age 73)Mr. Garrison J. Hasara CPA, CPA, CFO, Treasurer, Sec. & Chief Compliance Officer (Age 50) What is Inhibitor Therapeutics' stock symbol? Inhibitor Therapeutics trades on the NASDAQ under the ticker symbol "INTI." How do I buy shares of Inhibitor Therapeutics? Shares of INTI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Inhibitor Therapeutics' stock price today? One share of INTI stock can currently be purchased for approximately $0.04. How big of a company is Inhibitor Therapeutics? Inhibitor Therapeutics has a market capitalization of $15.93 million. Inhibitor Therapeutics employs 2 workers across the globe. View additional information about Inhibitor Therapeutics. What is Inhibitor Therapeutics' official website? The official website for Inhibitor Therapeutics is http://www.inhibitortx.com/. How can I contact Inhibitor Therapeutics? The company can be reached via phone at 813-864-2559. MarketBeat Community Rating for Inhibitor Therapeutics (NASDAQ INTI)Community Ranking: 1.4 out of 5 ()Outperform Votes: 3 (Vote Outperform)Underperform Votes: 8 (Vote Underperform)Total Votes: 11MarketBeat's community ratings are surveys of what our community members think about Inhibitor Therapeutics and other stocks. Vote "Outperform" if you believe INTI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INTI will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 3/28/2020 by MarketBeat.com StaffFeatured Article: Current Ratio
